ASX:IDXIntegral Diagnostics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Integral Diagnostics Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add A$3.31 -0.01 (-0.30 %) (As of 05/13/2020) Add Compare Share Today's RangeA$3.20Now: A$3.31▼A$3.3650-Day RangeA$3.31MA: A$3.31▼A$3.3152-Week RangeA$1.78Now: A$3.31▼A$4.39Volume240,828 shsAverage VolumeN/AMarket Capitalization$644.40 millionP/E Ratio26.27Dividend Yield2.60%BetaN/A ProfileAdvanced ChartCompetitorsDividendHeadlines Integral Diagnostics Limited, a healthcare services company, provides diagnostic imaging services to general practitioners, medical specialists, and allied health professionals and their patients in Australia. The company provides its services through a network of 53 sites under the Lake Imaging, South Coast Radiology, and Global Diagnostics brands in Victoria, Queensland, and Western Australia, as well as through specialist Radiology Group, and Trinity MRI and Cavendish Radiology in Auckland, New Zealand. Integral Diagnostics Limited is headquartered in North Melbourne, Australia.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Integral Diagnostics. Previous Next 2.5 Community Rank Outperform VotesIntegral Diagnostics has received 14 “outperform” votes. (Add your “outperform” vote.)Underperform VotesIntegral Diagnostics has received 14 “underperform” votes. (Add your “underperform” vote.)Community SentimentIntegral Diagnostics has received 50.00% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Integral Diagnostics and other stocks. Vote “Outperform” if you believe IDX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe IDX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.8 Dividend Strength Dividend YieldIntegral Diagnostics pays a meaningful dividend of 2.60%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthIntegral Diagnostics does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Integral Diagnostics is 79.37%. Payout ratios above 75% are not desirable because they may not be sustainable. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Integral Diagnostics insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Integral Diagnostics are expected to decrease by -100.00% in the coming year, from A$0.10 to A$0.00 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Integral Diagnostics is 26.27, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 16.42.Price to Earnings Ratio vs. SectorThe P/E ratio of Integral Diagnostics is 26.27, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 23.08.Price to Book Value per Share RatioIntegral Diagnostics has a P/B Ratio of 2.85. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.8Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.67 out of 5 stars Industry, Sector and Symbol Stock Exchange ASX Industry Diagnostics & Research Sub-IndustryN/A SectorMedical Current SymbolASX:IDX Previous Symbol CUSIPN/A CIKN/A Webwww.integraldiagnostics.com.au Phone61 3 5339 0704Debt Debt-to-Equity Ratio113.20 Current Ratio0.78 Quick Ratio0.66Price-To-Earnings Trailing P/E Ratio26.27 Forward P/E Ratio33.75 P/E GrowthN/A Sales & Book Value Annual Sales$249.55 million Price / Sales2.58 Cash FlowA$0.14 per share Price / Cash Flow23.99 Book ValueA$1.16 per share Price / Book2.85Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees928 Outstanding Shares194,684,000Market Cap$644.40 million Next Earnings DateN/A OptionableNot Optionable Receive IDX News and Ratings via Email Sign-up to receive the latest news and ratings for IDX and its competitors with MarketBeat's FREE daily newsletter. Integral Diagnostics (ASX:IDX) Frequently Asked Questions How has Integral Diagnostics' stock been impacted by COVID-19 (Coronavirus)? Integral Diagnostics' stock was trading at A$3.74 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, IDX shares have decreased by 11.5% and is now trading at A$3.31. View which stocks have been most impacted by Coronavirus. How often does Integral Diagnostics pay dividends? What is the dividend yield for Integral Diagnostics? Integral Diagnostics declared a Interim dividend on Friday, February 21st. Stockholders of record on Tuesday, April 7th will be paid a dividend of 0.055 per share on Tuesday, April 7th. This represents a dividend yield of 1.29%. The ex-dividend date of this dividend is Friday, February 28th. This is a positive change from Integral Diagnostics's previous Interim dividend of A$0.05. View Integral Diagnostics' dividend history. Has Integral Diagnostics been receiving favorable news coverage? News coverage about IDX stock has been trending negative this week, InfoTrie reports. The research group identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Integral Diagnostics earned a media sentiment score of -2.5 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 2.0 out of 10, meaning that recent media coverage is very unlikely to have an effect on the company's share price in the near term. View the latest news about Integral Diagnostics. Who are some of Integral Diagnostics' key competitors? Some companies that are related to Integral Diagnostics include Profound Medical (PRN), Renalytix Ai (RENX), Volpara Health Tech (VHT), Akumin (AKU), Exagen (XGN), MaxCyte (MXCT), Yourgene Health (YGEN), Senseonics (SENS), Palatin Technologies (PTN), Oncimmune (ONC), Lexagene (LXG), Oncosil Medical (OSL), Genedrive (GDR), SQI Diagnostics (SQD) and BARD1 Life Sciences (BD1). View all competitors. What other stocks do shareholders of Integral Diagnostics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Integral Diagnostics investors own include Westgold Resources (WGX), NRW (NWH), EML Payments (EML) and Bathurst Resources (BRL). Who are Integral Diagnostics' key executives? Integral Diagnostics' management team includes the following people: Dr. Ian Kadish, CEO, MD & Director (Age 56)Ms. Anne Lockwood, Chief Financial OfficerDr. Chien Ping Ho, Exec. DirectorDr. Sally Sojan, Exec. DirectorMrs. Kathryn Davies BBus, GAICD, CPA, Company Sec. What is Integral Diagnostics' stock symbol? Integral Diagnostics trades on the ASX under the ticker symbol "IDX." What is Integral Diagnostics' stock price today? One share of IDX stock can currently be purchased for approximately A$3.31. How big of a company is Integral Diagnostics? Integral Diagnostics has a market capitalization of $644.40 million and generates $249.55 million in revenue each year. Integral Diagnostics employs 928 workers across the globe. What is Integral Diagnostics' official website? The official website for Integral Diagnostics is www.integraldiagnostics.com.au. How can I contact Integral Diagnostics? The company can be reached via phone at 61 3 5339 0704. This page was last updated on 7/3/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
